# Cannabis and Coronary Thrombosis: Clinical Insights from a New Case Report > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-cardiovascular-safety-signal-case-report/ > **Published:** 2026-07-18T12:02:44-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T22:03:21-04:00 > **Clinical Summary:** Explore the cannabis cardiovascular safety signal from a 2026 case report detailing coronary thrombosis in a young cannabis user with a proposed mechanism. --- CED Clinical Relevance #68 Notable Clinical Interest A July 11, 2026 case report in the International Journal of Emergency Medicine describes a 34-year-old chronic cannabis user who presented with a large-vessel ST-elevation myocardial infarction and no significant underlying atherosclerosis. It is a single case, not a trial, but it is a real, peer-reviewed clinical account that adds to a growing cardiovascular safety-signal literature clinicians should be aware of. Clinical Insight | CED Clinic This case report describes a 34-year-old chronic cannabis user who developed an extensive coronary thrombosis with ST-elevation myocardial infarction in the absence of significant coronary atherosclerosis on angiography. The authors propose that cannabis-associated thrombosis may involve catecholamine surge and vasospasm, endothelial dysfunction, and direct platelet activation through CB1 and [CB2 receptors](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/), which can increase thromboxane A2 and P-selectin expression. The clinical value of a single case report is narrow: it cannot establish causation, estimate risk in the broader population of cannabis users, or rule out confounders such as tobacco co-use, stimulant use, or undiagnosed clotting disorders. Its value is in pattern recognition, prompting clinicians to ask about cannabis use when a young patient without conventional cardiac risk factors presents with an unexplained large-vessel thrombotic event. Cardiovascular SafetyCase ReportTHCEmergency Medicine[Cannabinoid Receptors](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/) Audience Primary care and emergency physicians evaluating young adults with chest pain or acute coronary syndrome, cardiologists, and patients or families with questions about cannabis and cardiovascular risk. Primary Topic A July 11, 2026 case report describing extensive coronary thrombosis and STEMI in a young chronic cannabis user, with a proposed CB1/CB2-receptor-mediated prothrombotic mechanism. Source [Read the full PubMed record](https://pubmed.ncbi.nlm.nih.gov/42436387/) Table of Contents - [Cannabis and Coronary Thrombosis: What a New Case Report Does and Doesn’t Show](#Cannabis_and_Coronary_Thrombosis_What_a_New_Case_Report_Does_and_Doesn8217t_Show) - [How to Read a Single Case Report Without Overreacting or Dismissing It](#How_to_Read_a_Single_Case_Report_Without_Overreacting_or_Dismissing_It)[Four questions to ask before summarizing this case](#Four_questions_to_ask_before_summarizing_this_case) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[One Case Is a Signal, Not a Verdict](#One_Case_Is_a_Signal_Not_a_Verdict) - [Ask About Cannabis in Unexplained Young-Adult ACS](#Ask_About_Cannabis_in_Unexplained_Young-Adult_ACS) - [A Vasospastic and Prothrombotic Picture, Not a Plaque-Rupture Picture](#A_Vasospastic_and_Prothrombotic_Picture_Not_a_Plaque-Rupture_Picture) - [Case Reports Generate Hypotheses, They Do Not Test Them](#Case_Reports_Generate_Hypotheses_They_Do_Not_Test_Them) - [What Wasn’t Ruled Out Matters As Much As What Was Found](#What_Wasn8217t_Ruled_Out_Matters_As_Much_As_What_Was_Found) - [Add Cardiovascular Risk to Cannabis Counseling, Proportionately](#Add_Cardiovascular_Risk_to_Cannabis_Counseling_Proportionately) - [The Field Needs Incidence Data, Not More Isolated Cases](#The_Field_Needs_Incidence_Data_Not_More_Isolated_Cases) - [Rising Potency Makes This Worth Ongoing Attention](#Rising_Potency_Makes_This_Worth_Ongoing_Attention) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## Cannabis and Coronary Thrombosis: What a New Case Report Does and Doesn’t Show A July 11, 2026 case report in the International Journal of Emergency Medicine describes a 34-year-old chronic cannabis user who developed a large coronary thrombus and a major heart attack with no significant atherosclerosis on angiography. The authors propose a cannabinoid-receptor-mediated prothrombotic mechanism. As with any single case, it cannot prove causation, but it adds to a real and growing cardiovascular safety signal. What This Study Teaches Us This case teaches that a single, well-documented clinical report can be clinically useful for pattern recognition even though it cannot establish population-level risk. It also teaches the specific proposed mechanism: cannabinoid receptor-mediated platelet activation and vasospasm as a plausible pathway from cannabis exposure to acute large-vessel thrombosis. Why This Matters Emergency and primary care clinicians do not always ask about cannabis use when a young adult presents with acute coronary syndrome, because conventional risk-factor screening is built around cholesterol, smoking, diabetes, and family history. This case is a reminder that large-vessel thrombosis can occur in young cannabis users without any of those conventional risk factors, and that a [cannabis history](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) is worth asking about specifically in this presentation. Study Snapshot Study Type Single patient case report Patient 34-year-old man, chronic cannabis user Presentation Acute anterior ST-elevation myocardial infarction Angiography Finding Large thrombus in the left main and proximal LAD with complete mid-LAD occlusion (TIMI 0), no significant atherosclerosis Treatment Intracoronary streptokinase (300,000 IU) plus intravenous streptokinase (1,200,000 IU), restoring TIMI II flow Outcome Uneventful recovery on dual antiplatelet therapy, a statin, and anticoagulation Proposed Mechanism Catecholamine surge and vasospasm, endothelial dysfunction, and CB1/CB2-receptor-mediated platelet activation with increased thromboxane A2 and P-selectin expression Journal International Journal of Emergency Medicine Published July 11, 2026 PMID 42436387 DOI 10.1186/s12245-026-01275-1 Clinical Bottom Line A single case cannot prove that cannabis caused this patient’s heart attack, but the angiographic picture, the proposed platelet-activation mechanism, and the absence of conventional cardiac risk factors make this a legitimate cardiovascular safety signal worth clinical attention, not a basis for a categorical causal claim. What Happened In This Case A 34-year-old man with a history of [chronic cannabis use](https://cedclinic.com/cannabis-tolerance-behavioral-models/) presented with an acute anterior ST-elevation myocardial infarction. Coronary angiography showed a large thrombus involving the left main and proximal left anterior descending arteries, with complete occlusion of the mid-LAD (TIMI 0 flow). Given the extensive thrombus burden, clinicians treated him with intracoronary streptokinase followed by an intravenous dose, which produced significant thrombus resolution and restored TIMI II flow. He recovered without complication on dual antiplatelet therapy, a statin, and anticoagulation. The Proposed Mechanism The authors propose that cannabis-associated thrombosis may involve several interacting pathways: a catecholamine surge causing tachycardia and vasospasm, endothelial dysfunction, and direct platelet activation through CB1 and [CB2 receptors](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/) that increases thromboxane A2 and P-selectin expression. Notably, angiography did not show significant atherosclerotic plaque, which is part of what makes this case distinct from a typical plaque-rupture heart attack and points instead toward a vasospastic and prothrombotic process. What Made This Case Notable This was a large-vessel occlusion in a young adult without significant angiographic atherosclerosis and, as described, without the conventional cardiovascular risk factors that typically prompt an aggressive workup in older patients. That combination, [chronic cannabis use](https://cedclinic.com/cannabis-tolerance-behavioral-models/) plus an unexplained large thrombus burden, is the pattern the authors want emergency and primary care clinicians to recognize. Why One Case Cannot Establish Causation A single case report has no control group, no denominator, and no way to quantify how often this occurs among the much larger population of people who use cannabis without any cardiac event. It cannot separate the effect of cannabis from other unmeasured factors. The report does not describe THC potency, route of administration, or co-use of tobacco, alcohol, or stimulants in detail sufficient to rule out contributing exposures. Case reports are hypothesis-generating, not hypothesis-confirming. How Clinicians Can Use This Now This case is a reasonable prompt to ask about cannabis use, frequency, and route of use when a young patient presents with acute coronary syndrome and no conventional risk factors, and to counsel patients with existing cardiovascular disease or risk factors about a plausible prothrombotic pathway. It is not a reasonable basis for telling all cannabis users they are at high risk of a heart attack. The honest clinical message is a specific one: an uncommon but real and mechanistically plausible cardiovascular risk exists, and it deserves the same clinical curiosity as any other unexplained thrombotic event. How Strong Is This Evidence? This is the weakest tier of clinical evidence discussed on CED Clinic: a single peer-reviewed case report rather than a cohort study, case-control study, or clinical trial. Its strength is clinical detail and plausibility, a well-documented angiographic picture, a specific and biologically coherent proposed mechanism, and publication in a peer-reviewed emergency medicine journal. Its weakness is generalizability. Nothing here establishes incidence, relative risk, or causation, and the finding should be weighted accordingly alongside the larger cohort and case-control literature on cannabis and cardiovascular risk. Where This Paper Deserves Skepticism A skeptical reader should notice what is missing as much as what is reported: no quantification of how much cannabis, how often, by what route, and no systematic exclusion of tobacco, stimulant use, or a clotting disorder. The proposed CB1/CB2 mechanism is biologically plausible and consistent with other literature, but plausibility is not proof from a single case. This report is best read as one more data point in an accumulating safety-signal picture, not as a standalone verdict on cannabis and cardiovascular risk. What This Paper Does Not Show This case report does not show that cannabis use causes coronary thrombosis in general, does not establish how common this event is among cannabis users, does not isolate cannabis from other possible contributing exposures in this specific patient, and does not provide a dose or potency threshold above which risk changes. How This Fits With the Broader Clinical Conversation This case joins a small but real body of case reports and cohort-level safety signals connecting cannabis use to adverse cardiovascular events, including prior CED coverage of a Wellens syndrome case and cohort data on heart attack risk among cannabis users. None of these individually prove causation, but taken together they support treating cannabis cardiovascular safety as a genuine, evolving clinical question rather than a settled non-issue, particularly as THC potency in commercial products has risen. Dr. Caplan’s Take *I take cardiovascular case reports like this one seriously without overreacting to them. A single case does not change how I counsel most patients, but it does change what questions I ask when a young, otherwise low-risk patient shows up with an unexplained thrombotic event.* *For patients already living with cardiovascular disease or significant risk factors, this is one more reason I discuss route of administration, frequency, and product potency as part of a broader cardiovascular safety conversation, not as a reason to categorically rule cannabis out for every patient.* What a Careful Reader Should Take Away A careful reader should take away a narrow, honest conclusion: a well-documented single case report describes a large coronary thrombus in a young cannabis user with a biologically plausible platelet-activation mechanism, and it is worth clinical attention as a safety signal, but it cannot and does not establish that cannabis use causes coronary thrombosis in general. Evidence Interpretation Guide ## How to Read a Single Case Report Without Overreacting or Dismissing It Case reports are the most common way rare but serious adverse events first enter the medical literature, but they are also the tier of evidence most easily overread in either direction. This report is most useful when it is read as a specific, plausible clinical pattern, not as a population-level risk estimate. ### Four questions to ask before summarizing this case **What exactly was observed?**A single young adult with a large coronary thrombus, no significant atherosclerosis, and a [chronic cannabis use](https://cedclinic.com/cannabis-tolerance-behavioral-models/) history. That is a specific clinical picture, not a statistic. **Is there a plausible mechanism?**Yes. CB1/CB2-mediated platelet activation, catecholamine-driven vasospasm, and endothelial dysfunction are biologically coherent and consistent with other cannabis cardiovascular literature. **What confounders were not ruled out?**Tobacco co-use, stimulant use, THC potency, route of administration, and undiagnosed clotting disorders were not detailed enough to exclude as contributors. **What claim is actually justified?**That this is a real, mechanistically plausible cardiovascular safety signal worth clinical curiosity, not that cannabis use causes coronary thrombosis as a general rule. The Research Question Can a single case report establish that cannabis use causes coronary thrombosis in young adults? The Patient Question If one person had a heart attack after using cannabis, does that mean cannabis caused it, or that cannabis is dangerous for everyone? The Bottom Line No. It means this specific case is worth understanding and asking about, not that causation has been proven or that risk applies uniformly to everyone who uses cannabis. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview Different readers are vulnerable to different kinds of overreading with a single case report. These eight lenses keep the case clinically useful without overstating what it proves. #### One Case Is a Signal, Not a Verdict A single case report describes what happened to one person. It is worth knowing about, especially if you have heart disease or cardiovascular risk factors, but it does not mean cannabis will cause a heart attack in every user. If you have cardiovascular risk factors, this is a good reason to talk with your clinician about your cannabis use as part of your overall cardiovascular picture. Lens takeaway Take the signal seriously without assuming it applies to you personally. #### Ask About Cannabis in Unexplained Young-Adult ACS This case supports adding cannabis use history to the differential when a young patient presents with acute coronary syndrome and no conventional risk factors. Large-vessel thrombosis without significant atherosclerosis is an atypical enough picture that it deserves a specific line of questioning beyond standard risk-factor screening. Lens takeaway A [cannabis history](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) belongs in the workup for unexplained young-adult ACS. #### A Vasospastic and Prothrombotic Picture, Not a Plaque-Rupture Picture The absence of significant atherosclerosis on angiography points toward vasospasm and platelet activation rather than the classic plaque-rupture mechanism seen in most STEMI cases. That distinction matters for how clinicians think about secondary prevention and ongoing risk in patients with a cannabis-associated thrombotic event. Lens takeaway Consider a vasospastic/prothrombotic mechanism when atherosclerosis does not explain the angiographic picture. #### Case Reports Generate Hypotheses, They Do Not Test Them A case report has no comparison group and no way to calculate risk. Its role in the evidence base is to flag a pattern worth studying, not to quantify how often it occurs. The next appropriate step is cohort or case-control data that can estimate incidence and control for confounders like tobacco and stimulant co-use. Lens takeaway Treat this as hypothesis-generating evidence, not confirmatory evidence. #### What Wasn’t Ruled Out Matters As Much As What Was Found The report does not detail THC potency, route of use, or co-use of tobacco or stimulants in enough depth to exclude these as contributors. A biologically plausible mechanism strengthens the case for taking the signal seriously, but plausibility alone does not substitute for ruling out confounders. Lens takeaway A plausible mechanism is not the same thing as an isolated cause. #### Add Cardiovascular Risk to Cannabis Counseling, Proportionately For patients with existing cardiovascular disease or significant risk factors, this case supports discussing route of administration, frequency, and product potency as part of routine counseling. It does not support telling every patient who could benefit from medical cannabis that they face a high cardiovascular risk. Lens takeaway Proportionate counseling, not blanket warnings, is the right clinical response. #### The Field Needs Incidence Data, Not More Isolated Cases The most useful next step is cohort or registry data that can estimate how often cannabis-associated coronary thrombosis occurs and identify which patient and product characteristics carry the highest risk. Until that data exists, case reports like this one will keep accumulating as a pattern rather than resolving into a clear risk estimate. Lens takeaway Incidence and case-control data are the needed upgrade from isolated case reports. #### Rising Potency Makes This Worth Ongoing Attention As commercial cannabis products have grown more potent, cardiovascular safety signals like this one deserve continued public health attention rather than dismissal as anecdotal. Clear, proportionate public communication about this signal helps patients make informed decisions without either panic or false reassurance. Lens takeaway Rising product potency is a reason to keep watching this signal, not to overstate it today. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabis+and+Coronary+Thrombosis%3A+What+a+New+Case+Report+Does+and+Doesn%27t+Show&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-coronary-thrombosis-case-report%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-coronary-thrombosis-case-report%2F) [BlueSky](https://bsky.app/intent/compose?text=Cannabis+and+Coronary+Thrombosis%3A+What+a+New+Case+Report+Does+and+Doesn%27t+Show%20https%3A%2F%2Fcedclinic.com%2Fcannabis-coronary-thrombosis-case-report%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Extensive coronary thrombosis following cannabis use in a young adult: a case report.](https://pubmed.ncbi.nlm.nih.gov/42436387/) Related Reading at CED Clinic Continue exploring the evidence [Cannabis-Induced Wellens Syndrome Case Report](https://cedclinic.com/cannabis-induced-wellens-syndrome-case-report/) An earlier CED review of a different single cardiac case linked to cannabis use, and why one case cannot prove causation. [Read the Wellens syndrome case](https://cedclinic.com/cannabis-induced-wellens-syndrome-case-report/) [Cannabis Users Face Substantially Higher Risk of Heart Attack (2025)](https://cedclinic.com/cannabis-users-face-substantially-higher-risk-of-heart-attack-2025/) Cohort-level context on cannabis and heart attack risk that sits above the case-report evidence tier. [Read the cohort study coverage](https://cedclinic.com/cannabis-users-face-substantially-higher-risk-of-heart-attack-2025/) [How Cannabis Use May Impact Heart Attack Risk and Cardiovascular Health](https://cedclinic.com/acute-cannabis-cardiovascular-effects-heart-attack-risk/) A broader CED overview of acute [cannabis cardiovascular effects](https://cedclinic.com/marijuana-use-and-cardiovascular-disease/) and clinical risk assessment. [Read the cardiovascular overview](https://cedclinic.com/acute-cannabis-cardiovascular-effects-heart-attack-risk/) ## Frequently Asked Questions What did this case report actually describe? A 34-year-old chronic cannabis user who developed a large coronary thrombus and an anterior ST-elevation myocardial infarction, with complete mid-LAD occlusion and no significant atherosclerosis on angiography. Does this prove cannabis caused the heart attack? No. A single case report cannot establish causation. It describes one documented event and a plausible mechanism, not proof of a causal relationship. What mechanism do the authors propose? A combination of catecholamine-driven vasospasm, endothelial dysfunction, and direct platelet activation through CB1 and [CB2 receptors](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/), which can increase thromboxane A2 and P-selectin expression. Why was the absence of atherosclerosis significant? It suggests the thrombus formed through vasospasm and platelet activation rather than the more common plaque-rupture mechanism seen in typical heart attacks, which is consistent with the proposed cannabinoid pathway. How was the patient treated? With intracoronary streptokinase followed by an intravenous dose, which produced significant thrombus resolution and restored TIMI II flow. He recovered on dual antiplatelet therapy, a statin, and anticoagulation. What confounders were not ruled out? The report does not detail THC potency, route of administration, or co-use of tobacco or stimulants in enough depth to exclude these as contributing factors. Should clinicians ask about cannabis use in young patients with unexplained heart attacks? This case supports doing so, particularly when conventional cardiovascular risk factors are absent and angiography does not show significant atherosclerosis. Does this mean all cannabis users are at high cardiovascular risk? No. The case describes an uncommon presentation in one patient. It is a safety signal worth clinical attention, not evidence of high risk across all cannabis users. How does this fit with other cannabis cardiovascular research? It adds to a small but real and growing body of case reports and cohort-level data linking cannabis use to adverse cardiovascular events, without individually proving causation in any one instance. What evidence would strengthen this signal? Cohort or case-control studies that can estimate how often this occurs among cannabis users and control for confounders such as tobacco and stimulant co-use, product potency, and route of administration. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).